RU2717570C2 - Синергистические комбинации ауристана - Google Patents

Синергистические комбинации ауристана Download PDF

Info

Publication number
RU2717570C2
RU2717570C2 RU2017112048A RU2017112048A RU2717570C2 RU 2717570 C2 RU2717570 C2 RU 2717570C2 RU 2017112048 A RU2017112048 A RU 2017112048A RU 2017112048 A RU2017112048 A RU 2017112048A RU 2717570 C2 RU2717570 C2 RU 2717570C2
Authority
RU
Russia
Prior art keywords
cancer
pharmaceutically acceptable
adc
methyl
auristatin
Prior art date
Application number
RU2017112048A
Other languages
English (en)
Russian (ru)
Other versions
RU2017112048A3 (enExample
RU2017112048A (ru
Inventor
Пуджа САПРА
Борис ШОР
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2017112048A publication Critical patent/RU2017112048A/ru
Publication of RU2017112048A3 publication Critical patent/RU2017112048A3/ru
Application granted granted Critical
Publication of RU2717570C2 publication Critical patent/RU2717570C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017112048A 2014-10-10 2015-09-29 Синергистические комбинации ауристана RU2717570C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062192P 2014-10-10 2014-10-10
US62/062,192 2014-10-10
PCT/IB2015/057457 WO2016055907A1 (en) 2014-10-10 2015-09-29 Synergistic auristatin combinations

Publications (3)

Publication Number Publication Date
RU2017112048A RU2017112048A (ru) 2018-11-15
RU2017112048A3 RU2017112048A3 (enExample) 2019-05-07
RU2717570C2 true RU2717570C2 (ru) 2020-03-24

Family

ID=54288858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017112048A RU2717570C2 (ru) 2014-10-10 2015-09-29 Синергистические комбинации ауристана

Country Status (12)

Country Link
US (1) US10617670B2 (enExample)
EP (2) EP3204005A1 (enExample)
JP (1) JP6784668B2 (enExample)
KR (1) KR20170058432A (enExample)
CN (1) CN107106685A (enExample)
AU (1) AU2015329625B2 (enExample)
BR (1) BR112017006113A8 (enExample)
CA (1) CA2907878A1 (enExample)
IL (1) IL251619B (enExample)
MX (1) MX2017004580A (enExample)
RU (1) RU2717570C2 (enExample)
WO (1) WO2016055907A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6190534B2 (ja) 2013-08-22 2017-08-30 ソニー株式会社 水溶性蛍光染料又は有色染料及びその使用方法
CN107580618A (zh) 2016-04-01 2018-01-12 索尼公司 超亮二聚或多聚染料
JP7069033B2 (ja) 2016-04-06 2022-05-17 ソニーグループ株式会社 スペーシングリンカー基を有する超明色ダイマーまたはポリマー染料
AU2017264861B2 (en) 2016-05-11 2021-09-23 Sony Group Corporation Ultra bright dimeric or polymeric dyes
US12018159B2 (en) 2016-07-29 2024-06-25 Sony Group Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
EP3691689A1 (en) 2017-10-05 2020-08-12 Sony Corporation Programmable dendritic drugs
JP7551056B2 (ja) 2017-10-05 2024-09-17 ソニーグループ株式会社 プログラマブルなポリマー薬物
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
JP2021503450A (ja) 2017-11-16 2021-02-12 ソニー株式会社 プログラム可能なポリマー薬
DK3717503T3 (da) * 2017-11-30 2024-01-22 Ladrx Corp Albumin-bindende prodrugs af auristatin E derivater
JP7813098B2 (ja) 2018-01-12 2026-02-12 ソニーグループ株式会社 生物学的に活性な化合物を含む剛性間隔基を有するポリマー
JP2021510698A (ja) 2018-01-12 2021-04-30 ソニー株式会社 生物学的に活性な化合物を含むホスホアルキルリボースポリマー
CN111565757A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的磷酸烷基聚合物
KR102742386B1 (ko) 2018-03-19 2024-12-16 소니그룹주식회사 형광 신호 향상을 위한 2가 금속의 사용
WO2019182766A1 (en) 2018-03-21 2019-09-26 Sony Corporation Polymeric tandem dyes with linker groups
KR102854332B1 (ko) 2018-06-27 2025-09-03 소니그룹주식회사 디옥시리보오스를 포함하는 링커 군을 갖는 중합체성 염료
EP3820944A1 (en) 2018-07-13 2021-05-19 Sony Corporation Polymeric dyes having a backbone comprising organophosphate units
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
JP7816141B2 (ja) 2019-09-30 2026-02-18 ソニーグループ株式会社 ヌクレオチドプローブ
JP7556194B2 (ja) * 2019-12-13 2024-09-26 Ｔｏｐｐａｎホールディングス株式会社 細胞構造体及びその使用
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141044A2 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2012054748A2 (en) * 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
WO2013072813A2 (en) * 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463615C (en) 2001-10-30 2011-07-26 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
EP3434275A1 (en) * 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
AU2006287416A1 (en) * 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
WO2008002578A2 (en) 2006-06-26 2008-01-03 Nielsen Media Research, Inc. Methods and apparatus for improving data warehouse performance
AU2007297212B8 (en) 2006-09-15 2011-04-28 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
AU2008308163B2 (en) 2007-10-02 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
AU2009248993C1 (en) * 2008-05-23 2013-10-03 Wyeth Llc Triazine compounds as PI3 kinase and mTOR inhibitors
SG185428A1 (en) * 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
SG10201605401WA (en) 2011-04-01 2016-08-30 Wyeth Llc Antibody-drug conjugates
PH12014500925A1 (en) * 2011-10-28 2014-06-09 Genentech Inc Therapeutic combinations and methods of treating melanoma
CA2890571A1 (en) * 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
EP3137114B8 (en) * 2014-04-30 2021-08-04 Pfizer Inc. Anti-ptk7 antibody-drug conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141044A2 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2012054748A2 (en) * 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
WO2013072813A2 (en) * 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D'AMATO V. et al. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models//Br J Cancer. 2014 Jun 10; 110(12): 2887-2895.Published online 2014 May 13. doi: 10.1038/bjc.2014.241. *
D'AMATO V. et al. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models//Br J Cancer. 2014 Jun 10; 110(12): 2887-2895.Published online 2014 May 13. doi: 10.1038/bjc.2014.241. HERZOG A. et al. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer//Clin Cancer Res. 2013 Jul 15;19(14):3808-19. doi: 10.1158/1078-0432.CCR-12-2716. Epub 2013 May 2., реферат. WATANABE K.et al.Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models//Clin Cancer Res. 2010 Feb 15;16(4):1170-8. doi: 10.1158/1078-0432.CCR-09-2482. Epub 2010 Feb 9. *
HERZOG A. et al. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer//Clin Cancer Res. 2013 Jul 15;19(14):3808-19. doi: 10.1158/1078-0432.CCR-12-2716. Epub 2013 May 2., реферат. *
WATSON AL. et al.Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity//Oncotarget. 2014 Mar 30;5(6):1502-14., реферат. *

Also Published As

Publication number Publication date
RU2017112048A3 (enExample) 2019-05-07
JP6784668B2 (ja) 2020-11-11
MX2017004580A (es) 2017-06-27
KR20170058432A (ko) 2017-05-26
JP2017530983A (ja) 2017-10-19
US10617670B2 (en) 2020-04-14
AU2015329625B2 (en) 2018-04-05
BR112017006113A2 (pt) 2017-12-19
BR112017006113A8 (pt) 2018-04-24
US20180228769A1 (en) 2018-08-16
CN107106685A (zh) 2017-08-29
RU2017112048A (ru) 2018-11-15
IL251619B (en) 2020-10-29
EP3549583A1 (en) 2019-10-09
IL251619A0 (en) 2017-06-29
AU2015329625A1 (en) 2017-04-13
EP3204005A1 (en) 2017-08-16
WO2016055907A1 (en) 2016-04-14
CA2907878A1 (en) 2016-04-10

Similar Documents

Publication Publication Date Title
US10617670B2 (en) Synergistic auristatin combinations
RU2745678C2 (ru) Способы лечения рака
JP2024161445A (ja) 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
KR20120115237A (ko) 암 치료 방법 및 조성물
Tarantelli et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B-and T-cell lymphoma models
RU2731908C2 (ru) Композиции апилимода и способы его использования при лечениии меланомы
EA026317B1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK
UA119537C2 (uk) ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
AU2019226212A1 (en) Combination of Pl3K inhibitor and c-Met inhibitor
US20160129003A1 (en) Pharmaceutical Combinations
CN106659716A (zh) 阿吡莫德组合物及其使用方法
AU2019201169A1 (en) Pim kinase inhibitor combinations
CN110996960A (zh) 第三代egfr酪氨酸激酶抑制剂和raf抑制剂的治疗组合
KR20220020332A (ko) 항-cd19 항체 약물 접합체 및 pi3k 억제제 또는 2차 제제를 포함하는 조합 요법
CN114302746A (zh) 包含抗cd25抗体药物缀合物和另一剂的组合疗法
KR20160101027A (ko) 제약 조합물
HK1242995A1 (en) Synergistic auristatin combinations
McCubrey et al. New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways
HK40064613A (en) Methods for treating cancer
CN117083283A (zh) 用于癌症治疗的联合疗法
Abrams et al. New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK
HK40046230A (en) IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT
Molife et al. 1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours